[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":367},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,81,107,132,164,184,209,233,261,293,319,341],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100631902","early-mobilization-following-elective-spine-surgery-trial-of-in-bed-cycling-100631902",false,"NCT07506720","Early Mobilization Following Elective Spine Surgery: Trial of In-bed Cycling","Early Mobilization Following Elective Spine Surgery: Prospective Randomized Trial of In-bed Cycling on Postoperative Day 1","Inclusion Criteria\n\nMale or female ≥ 18 years old.\n\nPostoperative #0 following elective spinal surgery: decompression with or without fusion, or fusion.\n\nPatient able to walk independently before surgery (does not require assistance from another person and does not use a wheelchair).\n\nPatient admitted directly from the operating room to the ward.\n\nHemodynamically stable:\n\nSystolic blood pressure (SBP): ≥ 90 mmHg and \\\u003C 140 mmHg\n\nOxygen saturation \\> 94%\n\nHeart rate: 50-100 bpm\n\nPatient approved for surgery after preoperative internal medicine evaluation.\n\nPatient alert and conscious.\n\nValid informed consent obtained.\n\nExclusion Criteria\n\nNon-ambulatory preoperatively.\n\nBody Mass Index (BMI) \\> 40 kg\u002Fm².\n\nAcute neurological spinal trauma.\n\nNon-neurological musculoskeletal impairment of the lower limbs (e.g., severe osteoarthritis, hip fracture, amputation) limiting the ability to pedal in bed.\n\nUncontrolled comorbidities preventing surgery or intervention (cardiovascular, respiratory, diabetes).\n\nExpected hospital stay of less than 2 days after surgery.\n\nSurgery-related complications: acute neurological deficit, dural tear, cerebrospinal fluid (CSF) leak, residual spinal instability.\n\nTransfer to intensive care unit or hemodynamic instability.\n\nPersistent hemodynamic instability: SBP \\\u003C 90 mmHg or \\> 200 mmHg, oxygen saturation \\\u003C 88%, heart rate \\\u003C 50 or \\> 100 bpm, temperature \\> 38°C.\n\nCapillary blood glucose outside target values: \\\u003C 4.0 or \\> 7.0 mmol\u002FL fasting or pre-meal, \\\u003C 5.0 and \\> 10.0 mmol\u002FL 2 hours post-meal.\n\nPatient confused, disoriented, or agitated.\n\nPatient already evaluated by physiotherapy for discharge planning or intensive functional rehabilitation.\n\nPatient in isolation.\n\nPatient already discharged.","ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if early mobilization using an in-bed cycling device can reduce the amount of time patients spend in bed after elective spine surgery in adults.\n\nThe main questions it aims to answer are:\n\nDoes in-bed cycling on the day after surgery reduce the amount of time patients spend in bed over the next 24 hours?\n\nDoes in-bed cycling reduce the length of hospital stay and improve participation during physiotherapy assessment?\n\nResearchers will compare patients who receive an in-bed cycling session plus standard postoperative care to patients who receive standard postoperative care alone to see if early in-bed cycling improves mobility and recovery after spine surgery.\n\nParticipants will:\n\nBe randomly assigned to either a standard care group or an in-bed cycling group\n\nWear a fitness tracker to measure activity levels and time spent in bed\n\nReceive standard postoperative care\n\nComplete a 30-minute in-bed cycling session on the day after surgery (intervention group only)\n\nBe monitored for pain and vital signs during the study period\n\nUndergo a physiotherapy assessment to evaluate mobility and participation",[26,27,28],"Spine","Post Surgery Patients","Recovery Method",[30,31,32,33,34],"Spine Surgery","Postoperative Recovery","Early Mobilization","In-Bed Cycling","Kinesiophobia","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2025-08-01",{"date":43,"type":20},"2029-01",{"name":45,"class":46},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100637709","phase-2-ondansetron-for-the-prevention-of-patient-self-inflicted-lung-injury-in-patients-with-ards---pilot-rct-100637709","NCT07588217","Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT","A Pilot, Randomized, Controlled Clinical Trial Evaluating Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury Through Inhibition of Respiratory Drive in Patients With Acute Respiratory Distress Syndrome (OSIRIS-1)","OSIRIS-1","Inclusion Criteria:\n\n* Moderate-to-severe ARDS with all of the following:\n* Hypoxemic respiratory failure with PaO2:FiO2 \\\u003C 200 (on IMV with PEEP ≥ 5)\n* Precipitated within 1 week of an acute condition\n* Bilateral opacities on chest radiography and computed tomography or bilateral B lines and\u002For consolidations on ultrasound not fully explained by effusions, atelectasis, or nodules\u002Fmasses\n* Pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema\u002Ffluid overload\n* Hypoxemia\u002Fgas exchange abnormalities not primarily attributable to atelectasis\n* IMV initiated \\\u003C 96 hours\n* Extubation not anticipated within 24 hours\n\nExclusion Criteria:\n\n* Neuromuscular disease impairing spontaneous breathing\n* Pregnancy\n* Liver cirrhosis (Child B or C) or other severe impairment of hepatic function\n* Bradycardia (baseline pulse\\\u003C50\u002Fmin) on screening day\n* Known long QT syndrome\n* History of sustained ventricular tachycardia\n* Active digestive \u002F abdominal infection44\n* QTc prolongation \\> 470 msec in men and \\> 480 msec in women on screening day\n* On a medication at high risk of QT prolongation (Table 5)50\n* On two or more serotonergic medications (Table 6)51\n* Hypersensitivity \u002F intolerance to 5-HT3 antagonists\n* Patient deemed unlikely to survive past 24 hours or being transitioned to a fully palliative philosophy of care","75 Years",{"count":58,"type":20},76,[60,61],"PHASE2","PHASE3","Acute Respiratory Distress Syndrome (ARDS) is a serious condition where the lungs become inflamed, leading to severe breathing difficulties. Despite advances in medical care, ARDS remains a life-threatening illness with a high risk of death and long-term complications. One way doctors help ARDS patients is by using special ventilation techniques to protect the lungs from further damage. However, this often requires heavy sedation or even paralyzing medications, which can lead to other problems like delirium, muscle weakness, and longer hospital stays. Allowing patients to breathe on their own might offer benefits, but it also comes with risks. Many ARDS patients have a very strong urge to breathe, which can cause them to overexert their lungs, potentially leading to additional lung damage, known as patient selfinflicted lung injury (P-SILI). Our early research suggests that a medication called ondansetron, commonly used to prevent nausea, might help reduce this strong breathing drive in ARDS patients, possibly preventing further lung injury. The OSIRIS research program is designed to explore whether ondansetron can protect ARDS patients from P-SILI, ultimately improving their chances of survival and reducing long-term complications. The first part of this program, OSIRIS-1, is a small pilot study where we will test the feasibility of running a larger, more definitive trial. We will randomly assign ARDS patients to receive either ondansetron or a placebo, given intravenously four times a day, and monitor their heart rhythms closely to ensure safety. We will also track how well patients stick to the study plan and whether ondansetron helps reduce their breathing drive and lung strain. If successful, this research could lead to new ways of treating ARDS that rely less on heavy sedation, potentially improving outcomes for these critically ill patients and setting the stage for larger, more comprehensive studies in the future.",[64,65,66],"ARDS (Acute Respiratory Distress Syndrome)","Invasive Mechanical Ventilation","Patient-Self Inflicted Lung Injury",[68,69,70,71],"ondansetron","5HT3 antagonist","respiratory drive","respiratory effort","NOT_YET_RECRUITING","2026-05-08",{"date":75,"type":39},"2026-05-14",{"date":77,"type":20},"2026-10-01",{"date":79,"type":20},"2029-10-01",{"name":45,"class":46},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100632040","early-temporal-dynamics-of-optic-nerve-sheath-diameter-after-therapy-in-gca-100632040","NCT07508514","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis","SONIC-TIME","Inclusion Criteria:\n\n1. Participants must be enrolled in SONIC-GCA and must have:\n\n   * completed the baseline optic nerve sheath ultrasound\n   * confirmed GCA as determined by the baseline standardized GCA assessment in SONIC-GCA.\n2. Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline.\n3. Ability and willingness to provide written informed consent.\n4. Agreement to complete the SONIC-TIME intensive follow-up schedule.\n\nExclusion Criteria:\n\n1\\) Concurrent participation in a blinded interventional pharmaceutical clinical trial.","50 Years",{"count":91,"type":20},60,"OBSERVATIONAL","Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.\n\nThe SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.\n\nSixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.\n\nThe primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.",[95,96,97,98],"Giant Cell Arteritis","Temporal Arteritis","Optic Nerve Diseases","Diagnosis","2026-03-31",{"date":101,"type":39},"2026-04-02",{"date":103,"type":20},"2026-05-01",{"date":105,"type":20},"2028-05-01",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100481942","impact-of-vitamin-c-on-opiod-consumption-after-an-emergency-department-visit-for-acute-musculoskeletal-pain-100481942","NCT05555576","Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain","Impact of Vitamin C on the Reduction of Opioid Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain: A Double-Blind Randomized Control Trial Protocol","Inclusion Criteria:\n\n1. Aged 18 and over;\n2. Treated in ED for acute musculoskeletal pain present for less than 2 weeks;\n3. Discharged with an opioid prescription;\n4. Speaks French or English.\n\nExclusion Criteria:\n\n1. Opioid use 1 month prior to the ED visit;\n2. Already taking vitamin C supplement;\n3. Active cancer;\n4. Treated for chronic pain;\n5. Treated for opioid use disorder;\n6. Unable to fill out diary or unavailable for follow-up;\n7. Any allergy, intolerance or sensitivity to milk (lactose) or morphine\n8. Treated with cyclosporin or coumadin\n9. Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)",{"count":115,"type":20},464,[23],"Recent evidence has shown that vitamin C has some analgesic properties and can therefore reduce opioids used during healing. Vitamin C analgesic effect has been explored mostly during the short-term postoperative context or in disease specific chronic pain prevention but not after acute musculoskeletal injuries, which are often seen in the emergency department (ED).\n\nThe study's primary aim is to compare the total morphine 5 mg equivalent pills consumed during a two-week follow-up between patients receiving vitamin C or a placebo after ED discharge for an acute musculoskeletal pain complaint.\n\nThe investigators will conduct a double-blind randomized placebo-controlled trial with 464 participants distributed in two arms, one group receiving 1 000 mg of vitamin C twice a day for 14 days and another one receiving a placebo. Participants will be ≥18 years of age, treated in ED for acute musculoskeletal pain present for less than 2 weeks, and discharged with an opioid prescription for home pain management. Total morphine 5 mg equivalent pills consumed during the two-week follow-up will be assessed via an electronic (or paper) diary. In addition, patients will report their daily pain intensity, pain relief, side effects, and other types of pain medication or other non-pharmacological approach (ice, heat, immobilization, etc.) used. Three months after the injury, participants will also be contacted to evaluate chronic pain development. The investigators hypothesized that vitamin C, compared to a placebo, will reduce opioid consumption during a 14-day follow-up for ED discharged patients treated for acute pain.",[119],"Pain, Acute",[121,122,123,124],"Vitamin C","Opioids","Emergency department","Pain","2026-03-26",{"date":99,"type":39},{"date":128,"type":39},"2023-11-01",{"date":130,"type":20},"2026-12",{"name":45,"class":46},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100629308","protocol-for-rapid-onset-of-mobilization-in-patients-with-traumatic-spinal-cord-injury-ii-prompt-sci-ii-trial-100629308","NCT07472985","Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial","Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial: Initiating Early Acute Cycling Within the First Days After Spinal Cord Injury to Decrease Complications and Improve Neurofunctional Recovery","PROMPT-SCI II","Inclusion Criteria:\n\n* adults 18 years or older with non-penetrating traumatic SCI\n* SCI severity AIS grade A (complete injury with no motor or sensory function below lesion), B (sensory but no motor function preserved) or C (motor function preserved with most key muscles unable to move against gravity)\n* NLI between C0 and L2; and spine surgery performed within 48 hours of SCI\n\nExclusion Criteria:\n\n* intubated and mechanically ventilated\n* conditions interfering with patient safety or ability to undergo cycling\n* body mass index 40 kg\u002Fm2 or less (to prevent \"frog leg\" position during cycling)\n* moderate or severe traumatic brain injury\n* hemodynamic instability\n* pelvic or lower extremity\n* injury with weight-bearing or mobilization restrictions",{"count":141,"type":20},102,[23],"Spinal cord injuries (SCI) are among the most catastrophic survivable events experienced by human beings. Affected individuals remain with lifelong neurological impairment involving motor, sensory, bladder and bowel functions, which in turn impacts quality of life and independence. Currently, patients have no access to exercise therapy for weeks to months after the injury because clinicians remain fearful that early initiation of exercise therapy may be harmful to patients, and could lead to neurological deterioration. Patients are therefore mostly immobilized during the first weeks after the injury, and are at high risk of complications associated with immobility. In addition, there are compelling preclinical evidence showing that early exercise therapy is effective for promoting neurofunctional recovery. The PROMPT-SCI trial was the first to initiate early exercise therapy in the form of in-bed leg cycling within days after SCI. This trial has shown that it is safe and does not lead to neurological deterioration. However, in-bed leg cycling remains difficult to translate into the clinical environment of acute SCI, and its potential to decrease complications and improve neurofunctional recovery seems limited by the positioning in bed. The PROMPT-SCI II trial will therefore evaluate the potential of sitting leg cycling initiated within the first week of a SCI to decrease complications and improve neurofunctional recovery up to one year after the injury, in comparison to our prior data obtained with early in-bed cycling.",[145,146],"Spinal Cord Injuries","Spinal Cord Injury (SCI), Initial Encounter",[148,149,150,151,152,153,154,155],"spinal cord injury","exercise","activity-based therapy","rehabilitation","complications","acute care","critical care","neuroplasticity","2026-03-17",{"date":158,"type":39},"2026-03-19",{"date":160,"type":20},"2026-03-09",{"date":162,"type":20},"2031-12-31",{"name":45,"class":46},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":47},"100524415","renin-guided-therapy-with-mineralocorticoid-receptor-antagonists-in-primary-aldosteronism---feasibility-study-100524415","NCT06108427","REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study","RETAME-PA","Inclusion Criteria:\n\n* Over 18 years of age\n* Diagnosis of PA, in accordance with clinical guidelines and local practice\n* Suppressed plasma renin prior to treatment initiation (plasma renin concentration \\>15 mIU\u002FL or \\>10 ng\u002FL, or plasma renin activity \\>1 ng\u002FmL\u002Fh)\n* Planned long-term treatment with mineralocorticoid receptor antagonist\n\nExclusion Criteria:\n\n* Prior use of mineralocorticoid receptor antagonist or any potassium-sparing diuretics in the past 3 months\n* Known intolerance or contraindication to mineralocorticoid receptor antagonist treatment\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2 (past 3 months)\n* Baseline serum potassium above \\> 4.8 mmol\u002FL (past 3 months)\n* Deemed medically unsafe to stop medications for the initiation of MRA as monotherapy\n* Pregnancy or breastfeeding\n* Participation in another study that is likely to affect renin or BP levels\n* Inability to provide consent due to cognitive impairment and\u002For language barrier.",{"count":172,"type":20},58,[23],"High blood pressure, or hypertension, can be caused by a condition called Primary Aldosteronism (PA), where the body produces too much of a hormone called aldosterone. People with PA have a higher risk of heart problems compared to those with regular high blood pressure. To treat PA, some patients need to take medicine called mineralocorticoid receptor antagonists (MRA) for the rest of their lives. While treatment with MRA is effective, it can have side effects like high levels of potassium in the blood, breast enlargement in men, menstrual problems in women, and reduced sex drive. Finding the right dose of MRA for each patient can be tricky.\n\nRecent observations suggest that when a hormone called renin goes up during MRA treatment, it might be a good sign. This is because renin is higher when the action of aldosterone is well blocked. But it's not certain if this happens because of the patient's unique characteristics or if it can truly be a way to know if the treatment is working.\n\nThis study aims to find out if guiding MRA treatment with renin levels leads to more patients having unsuppressed renin levels compared to the standard of care.\n\nThis is a multicentric pragmatic clinical trial. Patients with a new diagnosis of PA and low renin levels will be asked if there are willing to participate. Those with recent use of MRA, known MRA intolerance, severe kidney problems, or have high potassium levels will not be able to participate.\n\nParticipants will be randomized into two groups: one group will have their MRA treatment adjusted based on renin levels (the \"renin-guided\" group), and the other group won't have renin levels checked during treatment (the \"renin-blinded\" group). Both groups will aim to have their blood pressure under control and potassium levels in the normal range.\n\nThe main outcome is the proportion in each group with unsuppressed renin levels after 12 months. Other outcomes will be tested, such as changes in renin levels, how well the treatment works, and any safety concerns (like potassium levels, kidney function, side effects, and blood pressure changes). Different groups of patients will also be looked at separately, like men and women, different ages, races, and initial renin levels, to see if the approach works better for some people.\n\nThis study will help find a safe and effective way to treat PA with MRA. Choosing the right dose of MRA is important to adequately block aldosterone but also to avoid side effects.",[176],"Primary Aldosteronism","2026-03-16",{"date":156,"type":39},{"date":180,"type":39},"2024-04-25",{"date":182,"type":20},"2027-09",{"name":45,"class":46},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},"100539618","effect-of-vitamin-c-on-pain-reduction-after-an-emergency-department-visit-100539618","NCT06306183","Effect of Vitamin C on Pain Reduction After an Emergency Department Visit","Vitamin C for Acute Musculoskeletal Pain in Emergency Department Patients: A Triple-Blind Randomized Control Trial (VICAMED)","Vicamed","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Presenting to the ED with acute MSK pain of ≤ 48 hours duration at triage\n3. Verbal numerical rating scale pain intensity at triage of ≥ 4 on a 0-10 scale\n4. Triaged to the ambulatory section of the ED\n5. Able to communicate in French or English\n\nExclusion Criteria:\n\n1. Usage of Vit C supplements in the last week\n2. Active cancer\n3. Treated with opioids for any pain within 24 hours prior to recruitment\n4. Treatment for chronic pain\n5. Unable to fill out a pain intensity diary or unavailable for follow-up\n6. Allergy to milk (lactose in the placebo) or Vit C\n7. Treated with cyclosporine or warfarin\n8. Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis\n9. Hospitalized after clinician evaluation",{"count":193,"type":20},204,[23],"Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. Because of these limits, some patients receive opioids, which can cause side effects and carry a risk of dependence. Safer and more accessible options are needed.\n\nVitamin C is widely known for supporting the immune system, but research suggests it may also help reduce pain and inflammation. Studies in surgical patients have shown that vitamin C can lower pain levels, reduce the need for opioids, and support healing. These effects may be linked to its antioxidant properties and its role in tissue repair. However, no study has tested whether vitamin C can help people with recent MSK injuries treated in the emergency department.\n\nThe VICAMED study aims to answer this question. Adults arriving with an MSK injury that occurred within the past 48 hours can participate if they have at least moderate pain. Participants are randomly assigned to receive either vitamin C or a placebo. The first dose is given in the emergency department, followed by twice daily capsules for three days. Pain is measured using a simple 0-100 scale, recorded in an electronic or paper diary. A follow-up on day six helps the research team understand each participant's recovery, medication use, and overall experience.\n\nVitamin C is inexpensive, widely available, and very safe at the doses used in this study. If it proves effective, it could offer a simple, low risk option to help patients manage pain after an MSK injury and reduce the need for opioids in emergency care.",[119],[121,198,123,124,199],"NSAID","RCT","2026-02-27",{"date":202,"type":39},"2026-03-02",{"date":204,"type":39},"2025-09-01",{"date":206,"type":20},"2029-12",{"name":45,"class":46},4,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100496811","optic-nerve-sheath-ultrasound-in-giant-cell-arteritis-100496811","NCT05749094","Optic Nerve Sheath Ultrasound in Giant Cell Arteritis","The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis","SONIC-GCA","Our population of interest is patients referred from any settings for suspected, new-onset GCA.\n\nInclusion criteria:\n\nTo be included in SONIC-GCA, participants must meet all the following criteria:\n\n1. Age \\> 50 years.\n2. Referral to a GCA clinic for suspected, new-onset GCA.\n3. Ability to understand and willingness to sign an informed consent form.\n4. Willingness to comply with study visits and procedures.\n\nExclusion criteria:\n\nAn individual who meets any of these criteria will be excluded from SONIC-GCA:\n\n1. Referral for a suspected GCA relapse.\n2. Current use of systemic glucocorticoids, with the following duration at the baseline visit: ≥ 14 consecutive days of oral glucocorticoids in the previous 30 days, or ≥ 7 consecutive days of oral glucocorticoids if intravenous glucocorticoids were administered in the previous 30 days.\n3. Current use of any conventional or biologic immunosuppressive therapy.\n4. Known previous medical history of retinal diseases, optic nerve diseases, demyelinating diseases, normotensive hydrocephalus, intracranial tumors (benign or malignant), or any conditions associated with intracranial hypertension.\n5. Any condition that impairs the ability to perform optic nerve sheath ultrasound or fundoscopy.","99 Years",{"count":219,"type":20},285,"The Sonographic Assessment of the Optic Nerve Sheath in Giant Cell Arteritis (SONIC-GCA) study will evaluate the performance of the optic nerve sheath diameter (ONSD), measured via ultrasound, to diagnose and monitor GCA. SONIC-GCA builds upon our previous pilot studies and will answer the following questions:\n\n1. What is the performance of ONSD to identify patients with new-onset, active GCA?\n2. Is ONSD useful for monitoring GCA relapses during follow-up?\n3. What is the intra- and interobserver reliability of ONSD measurements?\n4. Does ONSD differ between patients with and without GCA-related retinal findings?",[95,222,223],"Anterior Ischemic Optic Neuropathy","Optic Neuropathy, Ischemic","2025-08-02",{"date":226,"type":39},"2025-08-07",{"date":228,"type":20},"2025-08",{"date":230,"type":20},"2029-03",{"name":45,"class":46},6,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":47},"100550580","phase-2-cannabidiol-after-multi-trauma-for-pain-and-opioid-therapy-100550580","NCT06448923","Cannabidiol After Multi-Trauma for Pain and Opioid Therapy","Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture: a Triple-blind Randomized, Placebo Controlled Clinical Trial","CAM-POT","Inclusion Criteria:\n\n* Patients with a long bone fracture of the lower limb (tibia, fibula, femur, metatarsals, and phalanges) or the upper limb (humerus, radius, ulna, metacarpals, and phalanges) treated to Sacre-Coeur Hospital in Montreal (HSCM) within one week of the accident\n* Participants is between 18 and 70 years of age\n* Patients with or without surgical procedures\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere traumatic brain injury (TBI)\n* Diagnosis of any of the following mental disorders as defined by the DSM-5: schizophrenia, intellectual disability, bipolar disorder, major depression, a diagnosed and untreated sleep disorders\n* History of alcohol or opioid misuse\u002Fabuse, as defined by the DSM-5\n* Evidence of severe renal (stage 4 or 5) or hepatic impairment (Child B or C)\n* Pregnant or lactating women, women of childbearing potential who are not using medically accepted forms of contraception (e.g., condoms, oral contraceptive or intrauterine device), or women who are actively planning on becoming pregnant\n* History of adverse reactions to cannabis\n* Patients taking warfarin, sildenafil, valproate or under opioids treatment prior to the injury\n* Patients experiencing on average mild-to-absent pain in the last 24h preceding recruitment (as per a score \\\u003C30 on a 0-100mm Visual Analogue Scale (VAS))\n* Transport business drivers and heavy machinery operators\n* A diagnosis of chronic pain, bone pathology (e.g., osteoporosis) or chronic inflammatory disease (e.g., rheumatoid arthritis, arthritis, psoriasis)\n* Not having French or English as a spoken language\n* A weighted MoCA score of less than 24\n* Regular cannabis use more than 5 times a week","70 Years",{"count":243,"type":20},225,[60],"The aim of this project is to investigate the therapeutic potential and safety of acute Cannabidiol (CBD) treatment on longitudinal pain symptoms, and to assess potential interactions with pain mediators including opioids and sex on CBD treatment response. To this end, this research protocol proposes a comprehensive translational approach including a placebo-controlled randomized clinical trial comparing two daily doses of CBD treatment administered for one month on pain relief. This study will also compare intervention conditions on inflammation markers, participant quality of life, sleep quality, depression, anxiety, cognition and orthopaedic function.",[247],"Fracture",[249,250,124,251,247,252],"Cannabidiol","Trauma","Inflammation","Orthopaedic","2025-07-28",{"date":255,"type":39},"2025-07-30",{"date":257,"type":39},"2025-06-01",{"date":259,"type":20},"2027-06",{"name":45,"class":46},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":268,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":21,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":47},"100586834","postpartum-co-rehabilitation-100586834","NCT06920537","Postpartum CO Rehabilitation","Postpartum Cardio-obstetric Rehabilitation After Hypertensive Pregnancy","Inclusion Criteria:\n\n* are 3 to 6 months postpartum, willing, and able to give informed consent for participation;\n* are more than 18 years old;\n* are able to access and use a computer, mobile phone and internet (for online sessions);\n* were diagnosed with GH (BP higher than 139\u002F89 mmHg after 20 gestational weeks) or PE (BP higher than 139\u002F89 mmHg and proteinuria after 20 gestational weeks) during pregnancy.\n\nExclusion Criteria:\n\n* have chronic (pre-existing) hypertension (BP\\>139\u002F89 mmHg pre-pregnancy, \\\u003C20 weeks' gestation or after 6 weeks postpartum);\n* received antihypertensive drug therapy prior to pregnancy or after 6 weeks postpartum;\n* are taking beta-blockers for any reason;\n* participated in exercise activity programs regularly before 3-month postpartum (more than 2 hour of moderate-to-vigorous exercise per week);\n* have any musculoskeletal injury that can limit or contraindicate the practice of exercise;\n* have any major contraindications to exercise such as cardiomyopathy, cardiac arrhythmias and conduction abnormalities or congenital heart disease.","FEMALE",{"count":270,"type":20},40,[23],"Some women who develop high blood pressure during pregnancy, such as gestational hypertension or preeclampsia, may continue to have slightly or moderately high blood pressure after giving birth. This can increase their risk of heart disease later in life. Managing blood pressure and adopting a healthy lifestyle after pregnancy could help lower this risk.\n\nRight now, the investigators don't know much about how postpartum rehabilitation programs focused on heart and pregnancy-related health could help women with these conditions. However, a feasibility study suggests that exercise programs might help reduce blood pressure and encourage healthier lifestyles in these women.\n\nIn this study, the investigators are testing an 8-week exercise program to see how it affects blood pressure, fitness, and blood vessel health. The investigators will compare the results with a group of women who receive usual healthcare, which includes verbal advice on healthy living but no supervised exercise sessions.\n\nThis type of program, called cardio-obstetric rehabilitation, combines exercises for heart health with specialized care for women's health.",[274,275],"Gestational Hypertension","Preeclampsia (PE)",[277,278,279,280,281,282,283,284],"postpartum rehabilitation","physical exercise","blood pressure","Pelvic Floor","gestational hypertension","pre-eclampsia","small vessels","endothelial function","2025-05-12",{"date":287,"type":39},"2025-05-14",{"date":289,"type":20},"2025-06-15",{"date":291,"type":20},"2026-12-30",{"name":45,"class":46},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":47},"100568989","accuracy-testing-of-validated-and-non-validated-home-bp-devices-sold-on-the-online-market-100568989","NCT06688409","Accuracy Testing of Validated and Non-validated Home BP Devices Sold on the Online Market.","Comparing Home Blood Pressure Measurements from Devices with and Without Evidence of Validation to Ambulatory Blood Pressure Monitoring: the VALID-HomeBP Study","VALID-HomeBP","Inclusion Criteria:\n\n* Adults aged \\> 18 years scheduled to undergo an ABPM\n\nExclusion Criteria:\n\n* Upper arm size outside of cuff range of selected devices (\\\u003C22 cm or \\>42 cm)\n* Night shift workers\n* Permanent atrial fibrillation\n* Known severe aortic stenosis\n* Contraindication to measure BP on the non-dominant arm\n* Ongoing pregnancy\n* Inability or unwillingness to provide consent",{"count":302,"type":20},140,[23],"This study aims to assess whether validated and non-validated blood pressure measuring devices sold on the online market are accurate in regards to the mean awake BP from ambulatory blood pressure monitoring.",[306],"Hypertension",[308,309,279,310],"hypertension","blood pressure measurement","blood pressure device validation","2025-02-12",{"date":313,"type":39},"2025-02-14",{"date":315,"type":39},"2024-02-12",{"date":317,"type":20},"2027-11-30",{"name":45,"class":46},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":21,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100563763","phase-2-effects-of-dexmedetomidine-on-agitation-in-critically-ill-tbi-patients-100563763","NCT06620393","Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients","Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients (DEX-TBI)","DEX-TBI","Inclusion Criteria:\n\n1. Adults (≥18 years) admitted to ICU with a critically ill moderate or severe TBI patients. Severity of TBI will be determined with the first Glasgow Coma Score (GCS). TBI patients with polytrauma and patients undergoing neurosurgical interventions will be eligible.\n2. Undergoing mechanically ventilation (of any duration) at the time of assessment.\n3. Anticipated ICU stay of 48 hours or more.\n\nExclusion Criteria:\n\n1. Patients at very high risk of short-term mortality (e.g., GCS of 3 without sedation, or unreactive pupils, or declared brain-dead when assessed for eligibility and patients in whom there is a lack of commitment to ongoing life support\n2. Patients unable to communicate in English or French (interfering with posttraumatic amnesia assessments)\n3. Patients with cognitive impairment as per family evaluation\n4. Pregnant or breastfeeding\n5. Patients currently receiving DEX or clonidine\n6. Allergy, bradycardia or hypotension precluding use of dexmedetomidine as per treating physician",{"count":328,"type":20},72,[60,61],"Agitation is a frequent complication following traumatic braing injury in patients admitted to the intensive care unit. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine may be a better agent given it's light sedative properties. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU.",[332,333],"Traumatic Brain Injury","Agitation,Psychomotor","2024-09-27",{"date":336,"type":39},"2024-10-01",{"date":336,"type":20},{"date":339,"type":20},"2026-12-01",{"name":45,"class":46},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":47},"100559483","phase-4-early-pharmacological-treatment-of-acute-spasticity-after-spinal-cord-injury-100559483","NCT06564714","Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury","Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury to Promote Long-term Neurofunctional Recovery: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Male or female aged 18 years or older\n* Blunt (non-penetrating) traumatic SCI\n* AIS grade A to D\n* NLI between C0 and L1\n* Patient willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Non-traumatic SCI (e.g. tumor, infection, transverse myelitis, etc.)\n* AIS grade E upon admission\n* Penetrating tSCI (from stab wound, gunshot injury, etc.)\n* Cauda equina syndrome or NLI below L1\n* Moderate or severe brain injury (mild traumatic brain injury not an exclusion criteria)\n* Contraindication to oral baclofen use (needs clearance from attending physician and pharmacological consultant)\n* Pre-existing neurological disorders (cerebrovascular disease, Parkinson's disease, multiple sclerosis, etc.)\n* Major cognitive deficits precluding informed consent and\u002For assessments\n* Unlikely to comply with scheduled visits (e.g. living in another country)\n* Renal insufficiency",{"count":349,"type":20},55,[351],"PHASE4","The objective of this clinical trial is to evaluate if early detection of spasticity and immediate treatment with oral baclofen during acute care prevents problematic spasticity and improves neurofunctional recovery after tSCI.\n\nThe main questions it aims to answer are :\n\n1. Assess the safety of early baclofen treatment during acute care after SCI.\n2. Compare the neurofunctional outcomes between the early baclofen group and the control group up to 6 months after tSCI, in terms of mobility, global functional independence, neurological recovery, pain and spasticity.\n\nThe early baclofen group will receive oral administration of baclofen as soon as any sign of acute spasticity is observed. The dose is started initially at 5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic. The control group however will receive the \"usual routine care\" at our institution as per which baclofen is initiated by the attending physician (i.e. physiatrist or spine surgeon) only when acute spasticity becomes severe and problematic.",[354],"Traumatic Spinal Cord Injury",[250,356,357,358],"Spinal Cord Injury","Baclofen","Spasticity","2024-08-19",{"date":361,"type":39},"2024-08-21",{"date":363,"type":20},"2024-12",{"date":365,"type":20},"2029-06",{"name":45,"class":46},""]